Business Context and Reporting Period
Company: Ecolab Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 28, 2025
Reporting Period: Supplemental data provided for fiscal years ended December 31, 2024, and December 31, 2023, as well as quarterly data for 2024.
Key Financial Metrics
This filing does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notice of supplemental unaudited segment information provided in attached exhibits (Exhibit 99.1 and Exhibit 99.2). These exhibits present data reflecting:
- International operations at fixed currency exchange rates established by management at the beginning of 2025.
- Revised segment reporting structures effective in the first quarter of 2025.
The filing explicitly states that this information is supplemental and does not replace the financial data in the Company's Form 10-Q or Form 10-K filings.
Material Changes Versus Prior Period
The primary material change disclosed is a restructuring of the Company's reportable segments effective January 1, 2025. The new structure results in seven operating segments:
- Global Water: Renamed from "Global Industrial." Includes Light & Heavy (previously Water), Food & Beverage, and Paper operating segments.
- Global Institutional & Specialty: Continues to include Institutional and Specialty operating segments. The former healthcare operating segment has moved into the Institutional segment.
- Global Life Sciences: Elevated to a standalone reportable segment.
- Global Pest Elimination: Remains a standalone reportable segment.
Additionally, the supplemental data adjusts prior period results to reflect fixed currency exchange rates set at the start of 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing explains that the segment changes align with the Company's organizational structure of global business unit and market-based leadership teams. The Chief Operating Decision Maker reviews operating results at the identified segment level.
Legal Disclaimer: The financial information in this report and its exhibits is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not subject to the liabilities of that Section and shall not be incorporated by reference into other SEC filings unless expressly stated.
Guidance/Risks: The filing text does not provide specific forward-looking guidance, risk factors, or contingencies beyond the structural changes and the disclaimer regarding the status of the supplemental data.
Investor Verification Checklist
- Review Exhibit 99.1 and Exhibit 99.2 attached to this filing for the specific numerical values of the revised segment data.
- Verify the impact of the fixed currency exchange rates (established Jan 1, 2025) on the restated 2023 and 2024 results.
- Compare the new seven-segment structure against historical reports to understand the reclassification of the healthcare and Global Life Sciences segments.
- Confirm that the supplemental data is not intended to replace the official financial statements in the Form 10-K (for 2024) or Form 10-Q (for Q1-Q3 2024).